Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2009; 54:1747-1762, doi:10.1016/j.jacc.2009.05.015
© 2009 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Triposkiadis, F.
Right arrow Articles by Butler, J.
PubMed
Right arrow Articles by Triposkiadis, F.
Right arrow Articles by Butler, J.
Related Collections
Right arrowRelated Article

STATE-OF-THE-ART PAPER

The Sympathetic Nervous System in Heart Failure

Physiology, Pathophysiology, and Clinical Implications

Filippos Triposkiadis, MD*, George Karayannis, MD*, Grigorios Giamouzis, MD*,{ddagger}, John Skoularigis, MD*, George Louridas, MD{dagger} and Javed Butler, MD, MPH{ddagger},*

* Department of Cardiology, Larissa University Hospital, Larissa, Greece
{dagger} Department of Cardiology, AHEPA University Hospital, Thessaloniki, Greece
{ddagger} Cardiology Division, Emory University, Atlanta, Georgia

Manuscript received February 24, 2009; revised manuscript received May 11, 2009, accepted May 14, 2009.

* Reprint requests and correspondence: Dr. Javed Butler, Emory University Hospital, 1365 Clifton Road, NE, Suite AT430, Atlanta, Georgia 30322 (Email: javed.butler{at}emory.edu).

Heart failure is a syndrome characterized initially by left ventricular dysfunction that triggers countermeasures aimed to restore cardiac output. These responses are compensatory at first but eventually become part of the disease process itself leading to further worsening cardiac function. Among these responses is the activation of the sympathetic nervous system (SNS) that provides inotropic support to the failing heart increasing stroke volume, and peripheral vasoconstriction to maintain mean arterial perfusion pressure, but eventually accelerates disease progression affecting survival. Activation of SNS has been attributed to withdrawal of normal restraining influences and enhancement of excitatory inputs including changes in: 1) peripheral baroreceptor and chemoreceptor reflexes; 2) chemical mediators that control sympathetic outflow; and 3) central integratory sites. The interface between the sympathetic fibers and the cardiovascular system is formed by the adrenergic receptors (ARs). Dysregulation of cardiac beta1-AR signaling and transduction are key features of heart failure progression. In contrast, cardiac beta2-ARs and alpha1-ARs may function in a compensatory fashion to maintain cardiac inotropy. Adrenergic receptor polymorphisms may have an impact on the adaptive mechanisms, susceptibilities, and pharmacological responses of SNS. The beta-AR blockers and the inhibitors of the renin-angiotensin-aldosterone axis form the mainstay of current medical management of chronic heart failure. Conversely, central sympatholytics have proved harmful, whereas sympathomimetic inotropes are still used in selected patients with hemodynamic instability. This review summarizes the changes in SNS in heart failure and examines how modulation of SNS activity may affect morbidity and mortality from this syndrome.

Key Words: heart failure • sympathetic nervous system • adrenergic receptor • beta-blockers • sympatholytics • sympathomimetic inotropes

Abbreviations and Acronyms
  AR = adrenergic receptor
  ATP = adenosine triphosphate
  cAMP = 3',5'-cyclic monophosphate
  EPI = epinephrine
  MIBG = metaiodobenzylguanidine
  NE = norepinephrine
  SNS = sympathetic nervous system


Related Article

Inside This Issue
J. Am. Coll. Cardiol. 2009 54: A40. [Full Text] [PDF]





 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement